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Abstract
Heart failure (HF) is predominantly a disease of older adults and characterized by extensive sympatho-vagal imbalance leading to impaired 
reflex control of heart rate (HR). However, whether aging influences the development or extent of the autonomic imbalance in HF remains 
unclear. To address this, we used an ovine model of aging with tachypacing-induced HF to determine whether aging affects the chronotropic 
and inotropic responses to autonomic stimulation and reduction in heart rate variability (HRV) in HF. We find that aging is associated with 
increased cardiac dimensions and reduced contractility before the onset of tachypacing, and these differences persist in HF. Additionally, 
the chronotropic response to β-adrenergic stimulation was markedly attenuated in HF, and this occurred more rapidly in aged animals. By 
measuring HR during sequential autonomic blockade, our data are consistent with a reduced parasympathetic control of resting HR in aging, 
with young HF animals having an attenuated sympathetic influence on HR. Time-domain analyses of HR show a reduction in HRV in both 
young and aged failing animals, although HRV is lowest in aged HF. In conclusion, aging is associated with altered autonomic control and 
β-adrenergic responsiveness of HR, and these are exacerbated with the development of HF.
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In the healthy heart, stimulation of the sympathetic nervous sys-
tem via β-adrenergic pathways leads to an increase in heart rate 
(HR), force of contraction, and rate of relaxation. In general, oppos-
ing actions are mediated by the parasympathetic nervous system, 
with vagal stimulation slowing HR and decreasing contractility. 
Sympatho-vagal imbalance arising as a result of reduced parasym-
pathetic and increased sympathetic activity is a well-characterized 
feature of heart failure (HF), contributes to the systolic dysfunction 
associated with HF, and increasing sympatho-vagal imbalance is 
associated with progression towards the decompensated state (1,2). 
For example, the increased circulating levels of catecholamines and 
thus elevated sympathetic drive in HF lead to reduced responsive-
ness to β-adrenergic stimulation and a worsening of clinical symp-
toms (3,4). Moreover, targeting HF-associated sympatho-vagal 
imbalance through chronic vagal nerve stimulation appears to have 
therapeutic benefit in both experimental and clinical HF (5,6).
There is also evidence suggesting that aging leads to sym-
patho-vagal imbalance and mis-control of HR with impaired 
cardiac responsiveness to β-adrenergic stimulation noted (7–10). 
Furthermore, increased basal levels of circulating catecholamines 
and decreased β1-adrenoreceptor density have also been found with 
age (11). Aging is also a major risk factor for the development of 
HF (12). Despite the clear age dependency of HF, there is presently 
a paucity of information regarding whether alterations to the neu-
rohormonal axis that occur in aged animals with HF develop to the 
same degree, or with the same time dependency, as that which occurs 
in young animals with HF. These gaps in the literature exist primar-
ily because the majority of experimental research is carried out using 
only young animals. In this study, we have used a ventricular tachy-
pacing model of HF in both young and aged sheep to investigate 
any age dependency in the temporal development of sympatho-vagal 
imbalance in HF using in vivo techniques on conscious animals.
We find that aging is associated with an increase in resting HR, 
reduction in heart rate variability (HRV), and a reduced change 
in cardiac contractility in response to β-adrenergic stimulation. 
The development of HF increased HR, reduced HRV, attenuated 
the HR response to β-adrenergic stimulation, and abolished vagal 
tone in both young and aged sheep. However, the impairment of 
β-adrenergic responsiveness occurred earlier in aged sheep following 
induction of HF by tachypacing. Also, during complete pharmaco-
logically mediated autonomic blockade, the intrinsic HR was found 
to be increased in aging. We conclude therefore that HF leads to 
reduced catecholamine responsiveness in both the young and aged, 
but these effects develop more rapidly in the aged.
Methods
All procedures involving the use of animals were performed in accord-
ance with The United Kingdom Animals (Scientific Procedures) Act, 
1986 and European Union Directive 2010/63. Institutional approval 
was obtained from The University of Manchester Animal Welfare 
and Ethical Review Board. Furthermore, the study accords with the 
ARRIVE guidelines (13).
Experimental Model of Aging and HF
Female Welsh Mountain sheep (n  =  39; 34.8 ± 1.0 kg) aged either 
18 months (young, n = 23) or 8 years or older (aged, n = 16) were 
loose housed in groups of 4–5, fed ad libitum hay, and maintained on 
a 12-hour light, dark cycle at 20 ± 2°C. Animals were anesthetized with 
isoflurane (1%–5% v/v in oxygen), and preoperative analgesia was pro-
vided (meloxicom 0.5 mg/kg). A single active fixation bipolar IS-1 endo-
cardial pacing lead was placed trans-venously into the right ventricle 
and secured to a single chamber cardiac pacemaker with software mod-
ification (High Rate Pacing Patch, Medtronic Inc). To induce HF, right 
ventricular tachypacing was initiated at 210 beats per minute (bpm). 
In two animals, cardiac capture was not immediately consistent at 210 
bpm; we therefore paced these animals at 180 bpm for 2–7 days before 
increasing to 210 bpm for the remainder of the study. On presentation 
of clinical signs of HF (lethargy, dyspnea), tachypacing was stopped 
and a final “postpacing” set of in vivo experiments performed. Animals 
were humanely killed with pentobarbitone sodium (200 mg·kg−1) with 
10,000 units of heparin administered intravenously, and tissues were 
harvested for additional studies. For all in vivo assessments of cardiac 
function and sympatho-vagal balance following initiation of right 
ventricular tachypacing, pacemakers were switched off (ODO) for 15 
minutes before measurements were taken. All in vivo experiments were 
carried out on conscious, nonsedated, and gently restrained animals.
Echocardiography and Blood Pressure 
Measurements
Echocardiograms were analyzed offline using ImageJ (NIH, USA), 
and 3–20 consecutive cardiac cycles were averaged to obtain meas-
urements. Left ventricular (LV) end diastolic internal diameter 
(EDID), end systolic internal diameter (ESID), relative wall thickness 
(RWT), and fractional shortening measurements were all obtained 
from m-mode images, whereas the fractional area change was 
measured from short-axis images as we have described previously 
(4,14–17). Systolic and diastolic blood pressure measurements were 
recorded by tail cuff plethysmography. Readings were obtained over 
a 3- to 5-minute period, and the last three consistent values were 
averaged following European Society of Hypertension (ESH) and 
European Society of Cardiology (ESC) guidelines (18).
Measurement of HR and HRV
Surface electrocardiograms (ECGs) were recorded using a five-lead 
orthogonal configuration, digitized to personal computer (1 kHz), 
and the RR interval and HR were analyzed as described previously 
using shape recognition algorithms (ECG Auto, EMKA France) 
(17). Time-domain measures of HRV were quantified as RR interval 
standard deviation (RRSD) and the coefficient of variance of RRSD 
(RRSD / mean RR interval).
Assessment of Temporal Development of 
Sympathetic Dysfunction
The development of sympathetic dysfunction with tachypacing was mon-
itored weekly with intravenous infusions of the sympathetic agonist dob-
utamine (5–40 µg·kg−1·minute−1, Claris Life Sciences, UK). Dobutamine 
concentrations were increased in twofold increments up to a maximum 
of 40  μg·kg−1·minute−1 or until HR exceeded 150 bpm. ECGs were 
recorded for 5 minutes at each dobutamine dose, and ECG parameters 
were calculated from the last 60 seconds of each infusion period. Animals 
were allowed to recover for at least 30 minutes before tachypacing was 
recommenced. To assess whether sympathetic-mediated enhancement of 
cardiac contractility was altered with HF and aging, parasternal short-
axis echocardiograms were obtained at both baseline and immediately 
following the final infusion of dobutamine (5 µg·kg−1·minute−1 in control 
and 10–40 µg·kg−1·minute−1 in HF). Measurements were obtained both 
prior to tachypacing (control) and once HF had developed.
Assessment of Parasympathetic Influence of HR 
and HRV
Parasympathetic function in aging and HF was measured using sequen-
tial sympathetic (0.5 mg·kg−1 propranolol [PPL]; prepared as propran-
olol hydrochloride in 0.9% NaCl solution, Sigma-Aldrich, UK) and 
parasympathetic (0.05 mg·kg−1 atropine; prepared as atropine sulfate 
in 0.9% NaCl solution; Sigma-Aldrich) blockade via intravenous bolus 
with an additional 0.05 mg·kg−1·minute−1 atropine infused after 1 min-
ute to maintain complete autonomic block (AB) for the duration of 
the experiment. Measurements were obtained both prior to the start 
of tachypacing and once HF had developed. To determine whether AB 
was complete, HR responses to dobutamine (5 µg·kg−1·minute−1) and 
acetylcholine (100 nmol·min−1; prepared as acetylcholine chloride in 
0.9% NaCl; Sigma-Aldrich) were assessed in a subset of animals.
Quantification of Plasma Noradrenaline
Blood samples (~ 20 mL) were collected into K2EDTA vacutainer 
blood collection tubes by jugular venipuncture. Samples were stored 
on ice prior to centrifugation (4,000g, 10 minutes), and plasma were 
harvested and stored in liquid nitrogen until use. Plasma noradrena-
line was quantified using a competitive ELISA according to manufac-
turer’s instructions (Labor Diagnostika Nord, Germany).
Statistics
All data are presented as the mean ± SEM for n animals. All compari-
sons were made pair-wise on the same animal—that is, control versus 
HF as well as before and during drug infusions. Differences between 
groups (age, disease, and drug treatments) were analyzed using either 
a two-way repeated measures analysis of variance (ANOVA) firstly 
within each age group (eg, control vs HF; pre and post drug admin-
istration) and then between age groups (ie, young control vs aged 
control) or paired Student’s t test (autonomic blockade vs dobu-
tamine or acetylcholine). Data that were not normally distributed 
were transformed by means appropriate to the spread of data, for 
example, log10 (19). Differences were considered significant when p 
value was less than .05; however, p values were adjusted using the 
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Holm-Sidak post hoc test for multiple comparisons using SigmaPlot 
11.0. Correlational analysis was performed using GraphPad Prism 6.
Results
Signs of HF (lethargy and dyspnea) took a median of 35 days to 
develop (interquartile range = 9) with no age-dependent differences 
in the duration of tachypacing required to induce HF (p  =  .56). 
Tachypacing was not associated with any instances of sudden death, 
and all animals completed the study with none being excluded from 
subsequent data analysis.
As in our previous studies (4,14–17), aging and tachypacing-
induced HF were associated with increased LV dimensions and 
reduced contractile function (Table  1). Of note, aging by itself 
was associated with a 21% ± 7% increase in EDID, a 50% ± 15% 
increase in ESID, and a 15% ± 4% decrease in fractional shorten-
ing (all p < .01). In both age groups, HF increased (p < .001) EDID 
(young by 55.6% ± 10%; aged by 34.8% ± 6%) and ESID (young 
by 232% ± 21%; aged by 152% ± 20%) and resulted in a reduction 
(p < .001) in fractional shortening (young by 57% ± 2%; aged by 
59% ± 3%). However, ESID and fractional shortening were worst 
in the aged HF animals (p < .05). Finally, HF was associated with a 
decrease in RWT (p < .001; young by 51% ± 5%; aged by 41% ± 
5%). Systolic, diastolic, and mean blood pressure were decreased 
similarly with HF in both young and aged animals (all p < .001).
HR, HRV, and PR Interval Are Altered in the Ovine 
Model of Aging and HF
Surface five-lead orthogonal ECGs were measured both prior to 
tachypacing (control) and once HF was evident. Representative 
Poincaré plots of successive RR intervals from a young and an aged 
sheep are shown in Figure 1A. Resting HR was higher in aged than 
in young animals (Figure 1B. young, 105 ± 4 bpm; aged, 123 ± 7 bpm; 
p < .05). HF was associated with an increase in resting HR (122 ± 6 
bpm, pacemaker off) only in young animals (p < .05).
HRV measured in the time domain as the RRSD (Figure  1C) 
decreased with the development of HF in both age groups (young: 
control, 45 ± 6 ms; HF, 29 ± 5 ms; p < .01; aged: control, 29 ± 3 ms; HF, 
15 ± 2 ms; p < .01). However, although the observed differences in HRV 
(RRSD) did not reach significance in aged control animals compared 
with young control animals (p = .094), it was less in aged failing com-
pared with the young failing sheep (p < .01) and decreased overall with 
age (control and HF) compared with young (two-way ANOVA; p < .05)
Time-domain measures of HRV such as RRSD are influenced by 
the underlying HR (20–22), and we also see a strong correlation 
between RRSD and RR interval in sheep (Figure 1H–I; p < .001). 
We have therefore corrected for the age and HF-dependent changes 
in HR by normalizing the RRSD values to the mean RR interval 
in each animal (Figure 1D). We find that the coefficient of variance 
of the RRSD (20,21) indicates that the reduction in HRV in HF is 
not simply due to the increased HR (young: control, 0.074 ± 0.009; 
HF, 0.054 ± 0.009; p < .05; Aged: control, 0.057 ± 0.006; HF, 
0.031 ± 0.005; p < .001). Both measures therefore indicate a reduc-
tion of HRV in both young and aged animals with the development of 
HF. Furthermore, the coefficient of variance of RRSD was decreased 
overall in control and HF aged animals (two-way ANOVA, p < .05)
The final way in which we have assessed HRV in aging and HF 
is from the short-term (SD1), long-term (SD2), and ratio of short- 
to long-term variation of successive RR intervals obtained from the 
Poincaré plots (SD1:SD2; Figure 1E–G). Agreement with the previ-
ous assessments of HRV, these measures also show a decrease in 
HRV with age and HF, with the HF-dependent decrease in SD1:SD2 
ratio indicative of loss of parasympathetic influence on HR control 
being noted in both age groups.
In order to investigate whether conduction remodeling occurs 
in this model of HF, we quantified PR interval from the ECGs 
(Figure 1J). HF was associated with an increase in PR interval in both 
young (128.6 ± 3.3 ms vs 95.9 ± 3.2 ms) and aged (126.7 ± 4.8 ms vs 
102.6 ± 3.8 ms) sheep (both p < .001). However, no difference in PR 
interval was detected as a result of age (p = .57 by two-way repeated 
measures ANOVA).
Attenuated Chronotropic Responsiveness to 
β-Adrenergic Stimulation Occurs Early in the 
Development of HF by Tachypacing: An Effect 
Accelerated by Aging
We next sought to determine the time course of development and 
extent of sympathetic dysfunction in aging and with the onset of 
HF. This was assessed weekly by determining the HR responses to 
dobutamine (5–40 µg·kg−1·minute−1, Figure  2A). Before the onset 
of tachypacing to induce HF, dobutamine (5  µg·kg−1·minute−1) 
increased HR in both young and aged animals by 63% ± 14% 
in young and 42% ± 14% in aged (Figure 2B and C; p < .001 vs 
pre-dobutamine; p = .148 between age groups). Although this dose 
of dobutamine was still sufficient to increase HR compared with 
baseline after 1 week (p < .01) and 3 weeks (p < .05) tachypacing in 
the young, this was not the case for aged animals where, after just 
Table 1. Summary of Echocardiographic and Hemodynamic Findings in Aging and Heart Failure
Young Aged
Prepaced Postpaced Prepaced Postpaced
EDID (cm) 2.61 ± 0.10 3.91 ± 0.07*** 3.15 ± 0.15** 4.13 ± 0.10†††
ESID (cm) 0.92 ± 0.06 2.82 ± 0.10*** 1.38 ± 0.11** 3.17 ± 0.12†††,#
Fractional shortening 0.67 ± 0.02 0.29 ± 0.02*** 0.57 ± 0.02*** 0.23 ± 0.02†††,#
RWT 0.91 ± 0.08 0.39 ± 0.02*** 0.73 ± 0.06* 0.42 ± 0.05†††
Fractional area change 0.68 ± 0.02 0.38 ± 0.02*** 0.63 ± 0.02 0.36 ± 0.02†††
Systolic BP (mmHg) 127 ± 2.36 108 ± 2.27*** 133 ± 2.09 114 ± 2.62†††
Diastolic BP (mmHg) 79 ± 2.0 67 ± 1.64*** 84 ± 2.29 71 ± 2.36†††
Mean BP (mmHg) 95 ± 1.96 81 ± 1.70*** 100 ± 1.96 85 ± 2.17†††
Notes: Values are mean ± SEM from n = 16–18 young, 10–16 aged. Fractional shortening was calculated as (EDID − ESID) / EDID. RWT was calculated as (2 × 
diastolic wall thickness) / EDID. Fractional area change was calculated as (end diastolic area − end systolic area) / end diastolic area.
BP = blood pressure; EDID = end diastolic internal diameter; ESID = end systolic internal diameter; RWT = relative wall thickness. 
*p < .05 vs young prepaced. **p < .01 vs young prepaced. ***p < .001 vs young prepaced. †††p < .001 vs old prepaced. #p < .05 vs young postpaced.
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1 week of tachypacing, no change in HR was observed in response 
to 5  μg·kg−1·minute−1 dobutamine. We also noted that although 
there was a robust increase in HR in response to 5 μg·kg−1·minute−1 
dobutamine in both young and aged animals prior to commence-
ment of tachypacing, at the onset of HF, we found no change in 
HR response to doses of dobutamine less than 20 μg·kg−1·minute−1 
(Figure 2D); thus, the chronotropic response to β-adrenergic stimu-
lation is reduced in HF in both age groups although appears to 
occur earlier in the aged animals.
Sympathetic-mediated Inotropic Function Is 
Attenuated With Aging and HF
We next assessed whether the inotropic response to β-adrenergic 
stimulation, assessed as LV fractional area change, is attenuated 
in aging and with the development of HF (Figure 2E–G). In both 
young and aged animals, cardiac contractility (fractional area 
change) decreased with the development of HF with no age-
dependent temporal differences observed (Figure  2E). In young 
prepaced animals, 5  μg·kg−1·minute−1 dobutamine increased 
fractional area change by 31% ± 10%, whereas in aged con-
trol animals, this dose of dobutamine, despite its effect on HR, 
did not increase LV contractility significantly from baseline 
(p =  .129). On development of HF, the contractility response to 
catecholamine stimulation was assessed with an elevated dose of 
dobutamine which led to an increase of HR to 150 bpm (“the 
effective dose”; 20  µg·kg−1·minute−1 in 8 of 10 animals; range 
10–40 µg·kg−1·minute−1). In young HF animals, the effective dose 
of dobutamine (10–40 µg·kg−1·minute−1) increased contractility by 
Figure 1. Changes to baseline heart rate heart rate variability and PR interval. (A) Representative Poincaré plots of successive RR intervals in young (left) and 
aged (right) sheep before tachypacing (solid black circles) and in HF (open gray circles). (B–G) Summary data for young control (YC), young HF (YF), aged control 
(OC), and aged HF (OF) animals showing (B) mean HR, (C) RR standard deviation (RRSD), (D) coefficient of variance of RRSD, (E) instantaneous beat-to-beat 
HRV (SD1), (F) long-term beat-to-beat HRV (SD2), and (G) ratio of short- to long-term beat-to-beat HRV (SD1:SD2). (H) Mean values of RRSD as a function of RR 
interval. The solid line through the data is a best-fit regression of the form y = A + B · eC forced through the origin and having exponent (C) of 2.355. (I). Natural 
log RRSD as a function of mean RR interval with the solid line representing a linear regression to the data (p < .001). In panels (H) and (I) symbols denote: ○, YC; 
●, YF; □, OC; and ■, OF. (J) PR interval summary data. *p < .05 vs YC; **p < .01 vs YC; ***p < .001 vs YC; #p < .05 vs OC; ##p < .01 vs OC; ###p < .001 vs OC; $p < .05 
vs YF; $$p < .01 vs YF. n = 13–18 young, 9–11 aged.
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31% ± 13% (p < .05) and in aged HF sheep, the effective dose 
of dobutamine (20  µg·kg−1·minute−1) increased fractional area 
change by 29% ± 15% (p < .05). In both young and aged HF 
animals, despite the increased doses of dobutamine, the fractional 
area changes were considerably less than the 5 µg·kg−1·minute−1 
dobutamine responses observed before tachypacing commenced 
(p < .05). The attenuated chronotropic and inotropic responses 
to dobutamine in HF were also associated with a significant 
interaction between HF and plasma noradrenaline levels increas-
ing (Figure 2H; p < .05; two-way RM-ANOVA) with a directly 
observed increase in the aged cohort (aged control, 557 ± 73 
pg·mL−1; aged HF, 1973 ± 937 pg·mL−1; p < .05).
Parasympathetic Control of HR Is Lost With HF in 
Both Young and Aged Animals
Assessment of parasympathetic control of HR and HRV was made 
by sequentially blocking sympathetic and parasympathetic input 
with PPL and atropine, respectively, to achieve full autonomic block-
ade (AB, Figure 3A).
In young prepaced animals (Figure  3B), β-adrenergic receptor 
antagonism with PPL decreased HR by 29% ± 6% (p < .001) and 
subsequent full autonomic blockade led to a 60% ± 12% increase in 
HR (p < .001, compared with PPL). The mean intrinsic HR (ie, outwith 
autonomic influence) of young prepaced animals was 13% ± 7% faster 
than the resting HR (predrug administration; p < .05). In young HF 
Figure 2. Temporal development of sympathetic dysfunction in heart failure and aging.(A) Timeline of experimental protocol used to assess loss of sympathetic 
responsiveness in HF. White boxes indicate where ECGs were analyzed. (B, C) Summary data showing mean HR from animals at baseline (open circles) and in 
response to intravenous infusion of 5 μg·kg−1·minute−1 dobutamine (DOB, solid circles) in (B) young and (C) aged sheep. *p < .05; **p < .01; ***p < .001 vs baseline. 
(D) Summary data showing HR normalized to predobutamine infusion HR in young prepaced (open bar), aged prepaced (solid bar), young HF (striped bar), and 
aged HF (checked bar). **p < .01 vs normalized resting HR (ie, 1); ***p < .001 vs pre-DOB infusion HR. (E) LV contractility measured by fractional area change 
throughout the course of the rapid-pacing protocol in young (solid) and aged (open) sheep. Two-way repeated measures ANOVA detected a significant difference 
between fractional area change and weeks pacing (p < .001). (F, G). LV contractile function was assessed using 2D short-axis echocardiograms. Histograms showing 
summary data for mean fractional area change pre (−) and post (+) intravenous dobutamine (DOB) infusion in (F) young, (G) aged, control, and HF animals as 
indicated. **p < .01 vs Control pre-DOB; ***p < .001 vs Control pre-DOB; #p < .05 vs HF pre-DOB; $p < .05 vs Control post-DOB; $$$p < .001 vs Control post-DOB. (H) 
Summary data showing plasma noradrenaline concentrations determined by competitive ELISA. YC, young control; YF, young heart failure; OC, aged control; OF, 
aged heart failure. #p < .05 vs OC. For panels (A–D) and (F, G), n = 5 young, 5 aged, for panel (E) n = 7 young, 5 aged, and for panel (H), n = 9 young, 7 aged.
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animals, PPL still decreased HR (by 20% ± 6%, p < .001). However, 
this was a smaller reduction in HR than that seen before tachypacing 
commenced (p < .01), suggesting reduced sympathetic influence in HF. 
Furthermore, in the young HF animals, subsequent autonomic block-
ade failed to have any additional effect on HR (p = .955) indicating the 
loss of parasympathetic influence on HR control.
A broadly similar pattern was observed within the aged group 
(Figure 3C), with PPL slowing HR by 31% ± 6% compared with 
control conditions (p < .001) and autonomic blockade increas-
ing HR by 53% ± 11% compared with PPL (p < .001). However, 
unlike in the young control animals, the intrinsic HR of aged con-
trol animals, that is, during autonomic blockade, was not differ-
ent to the aged control resting HR (p =  .316). Furthermore, the 
intrinsic HR in aged control animals is greater than that in young 
control animals (young, 120.1 ± 4.1 bpm; aged 130.8 ± 3.0 bpm. 
Figure  3D, p < .05). In aged failing animals, PPL again slowed 
HR (by 29% ± 4%), but this was to a similar extent to that seen 
in the prepacing situation (p =  .154). In aged HF animals, auto-
nomic blockade failed to increase HR following PPL administra-
tion (p = .88). Thus HF in aged animals was associated with a loss 
of parasympathetic influence on HR, but sympathetic influence 
was unaltered.
The only age-dependent differences in HR noted were those pre-
sent at baseline (ie, prior to sympathetic or parasympathetic block-
ade). In both prepaced and postpaced time points, aged sheep had a 
higher HR than in the young sheep (both p < .05).
Figure  3. Heart failure and aging mediated parasympathetic dysfunction revealed by sequential autonomic blockade. (A) Schematic representation of 
experimental approach to achieve sympathetic and full autonomic blockade (AB). The white boxes indicate time periods used to analyze data. The horizontal 
break indicates assessment of responsiveness to dobutamine (DOB) or acetylcholine (ACh) following autonomic blockade performed in a subset of animals. (B) 
Summary data showing (upper panel) measured HR predrug administration (control, Con), after intravenous bolus of propranolol (PPL) and atropine (AB, full 
autonomic block) obtained prepacing (open symbols) and HF (closed symbols) in young animals and, (lower panel) tabulated significance values. (C) Summary 
data (upper panel) and tabulated significance data (lower panel) for aged animals (triangles, right). n = 13 young, 11 aged. (D) Mean intrinsic HR in aging and HF. 
*p < .05 vs YC; ***p < .001 vs YC; ###p < .001 vs OC. n = 13 YC, 13 YF, 15 OC, 11 OF. (E, F). Absence of heart rate responses to dobutamine infusion (E) or acetylcholine 
(F) following autonomic blockade (AB). NS, not significant. n = 4 each group.
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Importantly, the dosages of PPL and atropine used to achieve 
autonomic blockade were effective at preventing any HR responses to 
subsequent doses of dobutamine or acetylcholine (Figure 3E and F).
Parasympathetic Control of HRV Is Lost With the 
Development of HF
We also measured HRV from the RRSD/RR ratio following 
β-adrenergic receptor blockade and full autonomic blockade in 
young (Figure 4A) and aged (Figure 4B) animals. In young prepaced 
animals, no difference in HRV was detectable during β-adrenergic 
blockade with PPL, but HRV was reduced during full auto-
nomic blockade (control, 0.067 ± 0.007; PPL, 0.069 ± 0.012; AB, 
0.017 ± 0.007. All comparisons p < .001). A similar trend in HRV was 
seen in young failing animals following sequential β-adrenergic and 
full autonomic blockade (control, 0.056 ± 0.012; PPL, 0.049 ± 0.007; 
AB, 0.016 ± 0.002. All comparisons p < .01) such that, in young ani-
mals under full autonomic blockade, no differences in HRV exist 
between the prepaced and HF conditions.
As with the young prepaced sheep, no difference in HRV was 
found in aged prepaced animals following PPL, but HRV was 
less during full autonomic blockade (control, 0.051 ± 0.004; 
PPL, 0.061 ± 0.01; AB, 0.007 ± 0.001. All comparisons p < .001). 
However, in aged failing animals, neither PPL nor full autonomic 
blockade altered the coefficient of variation of RRSD (RRSD/mean 
RR; control, 0.031 ± 0.005; PPL, 0.025 ± 0.004; AB, 0.015 ± 0.002). 
The coefficient of variance of RRSD measure of HRV demonstrated 
that HRV was less at both baseline (no drug infusions) and follow-
ing β-adrenergic blockade in aged failing sheep compared with the 
prepacing values (p < .01).
The only age-dependent difference in the coefficient of variance 
of RRSD measurement of HRV following sequential β-adrenergic 
antagonism and full autonomic blockade was in HF both at baseline 
and after PPL administration. Thus HRV was less in aged HF ani-
mals than in young HF animals at baseline (no drug infusion) and 
following β-adrenergic receptor antagonism (p < .05). Following full 
autonomic blockade, HRV (coefficient of variance of RRSD) was the 
same in both young and aged HF animals.
Discussion
The aims of the present study were to determine whether aging 
influences the evolution of autonomic dysfunction during the 
development of HF. The major findings were (i) cardiac dimen-
sions are greater and indices of contractility are less in aged HF 
animals; (ii) chronotropic and inotropic responses to β-adrenergic 
stimulation are reduced in both aged and young animals with HF 
but develop earlier in the progression of tachypacing-induced HF 
in the aged; (iii) time-domain measures of HRV are reduced as a 
consequence of HF in both young and aged animals, but these are 
more pronounced in the aged, with some indices showing reduced 
HRV as a consequence of aging alone; and (iv) following sequential 
autonomic blockade to assess the sympatho-vagal influence on the 
control of HR we found subtle age-dependent differences in HF, 
although before tachypacing commenced the intrinsic HR (ie, dur-
ing full autonomic blockade) was greater than the resting HR in 
young animals. Together these findings indicate that there are sub-
tle age-dependent effects on (i) the extent of cardiac remodeling, 
(ii) β-adrenergic responsiveness, and (iii) autonomic control of HR 
with the development of HF.
Aging is known to influence a number of cardiac physiological 
and structural variables including the occurrence of cardiac fibrosis 
(17,23,24), mitochondrial dysfunction, (25) and in the context of the 
present study, impaired inotropic reserve and exercise intolerance; 
the latter being considered hallmarks of aging (8). The opposing 
Figure 4. Aging and heart failure mediated reductions in heart rate variability. (A) Summary data (upper panels) showing RRSD covariance values predrug 
administration (control, con), after propranolol (PPL) and atropine (full autonomic blockade, AB) in young prepaced (open bars) and HF (striped bars) and (lower 
panels) table of significance values for young animals. (B) Data (upper panels) and summary of significance (lower panels) for aged control (solid bars) and HF 
(checked bars) animals. n = 13 young, 11 aged.
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actions of the sympathetic and parasympathetic innervation of the 
heart ultimately determine HR and contribute to the beat-to-beat 
variability of HR, and these controlling factors are known to be 
altered by aging (26,27). We show that aging also influences these 
parameters in response to the development of HF. Specifically, using 
an ovine model of aging we show that HR is increased whereas time-
domain measures of HRV and the inotropic response to β-adrenergic 
stimulation are reduced. These findings are consistent with a dimin-
ished responsiveness to catecholamines in aging being observed at the 
cellular (28,29), tissue (8), and whole heart (30) levels. The elevated 
plasma catecholamine levels noted in some studies of aging [(31,32); 
Figure 2H] may be directly contributing to the decreased inotropic 
and chronotropic adrenergic responsiveness of the aged heart due to 
desensitization and internalization of the β-adrenergic receptors as 
has been previously noted in both aging (11) and HF (4).
A substantial body of evidence demonstrates that the elevated 
sympathetic drive in HF ultimately leads to a diminished myo-
cardial response to β-adrenergic stimulation, for example, see 
(3,4,33). In this study, we have demonstrated that the development 
of impaired β-adrenergic responsiveness occurs earlier in aged 
animals during the progression of HF. A  similar age-dependent 
attenuation of β-adrenergic influence on HR has been noted fol-
lowing exercise in patients (34). However, although the aged HF 
animals develop impaired inotropic and chronotropic responses to 
β-adrenergic stimulation earlier than the young HF animals, there 
are no age-dependent difference in β-adrenergic responsiveness 
once HF has developed, that is, HF results in a marked attenuation 
of the chronotropic response in both the young and aged. Thus 
aging may be an important factor determining the temporal devel-
opment, rather than ultimate outcome, of, impaired responsiveness 
to catecholamines as a result of pathological stresses such as HF.
Although we were unable to monitor the temporal development of 
impaired parasympathetic influence on HR control with the onset of 
tachypacing, we did note that, in both young and aged animals, there 
was a marked loss of the parasympathetic control of HR once HF had 
developed. Classically, the parasympathetic influence on the heart is to 
slow sinus node firing rate and thus HR. Additionally, the parasym-
pathetic input to the heart is also thought to determine the short-term 
variability of HR, albeit as a saturating function of parasympathetic 
activity (35,36). The increase in resting HR with age, as well as the 
unaltered HR following full autonomic block noted in aged animals, 
suggests that there is a reduced parasympathetic component to the 
control of HR in aging. Moreover, following tachypacing, there is a 
dramatic reduction/loss of parasympathetic input to controlling HR in 
both age groups, as demonstrated by (i) the marked reductions in sev-
eral time-domain measures of HRV and (ii) the failure of parasympa-
thetic blockade with atropine to influence HR following β-adrenergic 
blockade with PPL. Such observations are common to numerous stud-
ies of HF. However, the influence of aging on this response has been 
less well characterized (37); albeit that, at least in the present study, 
aging does not appear to influence this outcome once HF has devel-
oped. Given that reduced parasympathetic activity is generally held 
to indicate poor outcomes in HF, for example, see (38), the beneficial 
effects of chronic vagal nerve stimulation in HF may, in part, arise 
from the improved autonomic control of HR (6). Further studies are 
required to elucidate other cardioprotective mechanisms that may 
arise from vagal nerve stimulation.
Study Limitations
Although the tachypacing approaches are considered useful models 
of dilated cardiomyopathy and tachycardic cardiomyopathy (39), 
they do not replicate the most common cause of HF occurring as 
a result of myocardial ischemia. However, the autonomic perturba-
tions noted in the sheep model of aging and tachypacing-induced HF 
are consistent with those seen in other causes of HF and suggest a 
common effect on the sympatho-vagal control of HR independent of 
the underlying cause of this condition. Secondly, we did not perform 
weekly assessments of parasympathetic function (using autonomic 
blockade), during the development of HF due to the risk of arrhyth-
mias once tachypacing was resumed while animals were still subject 
to the effects of circulating PPL and atropine. However, the chrono-
tropic response to β-adrenergic stimulation was assessed weekly and 
demonstrated that sympathetic dysfunction arises very early in the 
development of HF. Finally, due to the orientation of the cardiac 
apex over the sternum, we were unable to obtain conventional tran-
sthoracic long-axis apical views of the heart by echocardiography 
and are therefore unable to satisfactorily determine a number of 
indices of cardiac function, for example, E/A ratios, torsion, and 
ejection fraction. Nevertheless, the long- and short-axis views that 
we have quantified clearly show a marked deterioration in cardiac 
function with aging and the development of HF.
Conclusion
In conclusion, we have demonstrated that aging results in car-
diac remodeling, reduced contractility, reduced HRV assessed by 
some time-domain analysis approaches, and reduced response to 
β-adrenergic stimulation. With the development of HF, we noted 
that aging is associated with a more rapid loss of the chronotropic 
response to β-adrenergic stimulation, greater cardiac dimensions, 
and impaired contractility, and finally, subtle changes in sympatho-
vagal imbalance compared with young HF animals. Taken together, 
given the age dependence of the development of HF in the general 
population, our findings suggest that aging is an important factor 
determining the development and extent of autonomic dysfunction 
in HF. The outcomes of current clinical trials targeting the vagal 
nerve may therefore be influenced by patient age.
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